Applications of Artificial Intelligence in Biotech Drug Discovery and Product Development
MedComm · 2025-08 · 6 (8)
DOI: 10.1002/mco2.70317 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 30.07.2025. Verfasst von Yuan-Tao Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Guangdong Key Laboratory of Nasopharyngeal C…. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 200 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Artificial intelligence (AI) is revolutionizing biotechnology by transforming the landscape of therapeutic development. Traditional drug discovery faces persistent challenges, including high attrition rates, billion‐dollar costs, and timelines exceeding a decade. Recent advances in AI—particularly generative models such as generative adversarial networks, variational autoencoders, and diffusion models—have introduced data‐driven, iterative workflows that dramatically accelerate and enhance pharmaceutical R&D. However, a comprehensive synthesis of how AI technologies reshape each key modality of drug discovery remains lacking. This review systematically examines AI‐enabled breakthroughs across four major therapeutic platforms: small‐molecule drug design, protein binder discovery, antibody engineering, and nanoparticle‐based delivery systems. It highlights AI's ability to achieve >75% hit validation in virtual screening, design protein binders with sub‐Ångström structural fidelity, enhancing antibody binding affinity to the picomolar range, and optimize nanoparticles to achieve over 85% functionalization efficiency. We further discuss the integration of high‐throughput experimentation, closed‐loop validation, and AI‐guided optimization in expanding the druggable proteome and enabling precision medicine. By consolidating cross‐domain advances, this review provides a roadmap for leveraging machine learning to overcome current biopharmaceutical bottlenecks and accelerate next‐generation therapeutic innovation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy Sun Yat-sen University Cancer Center Gu…
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
Zitieren
APA
Liu, Y. T., Zhang, L. L., Jiang, Z. Y., Tian, X. S., Li, P. L., Wu, P. H., Du, W. T., Yuan, B. Y., Xie, C., Bu, G. L., Zhong, L. Y., Yang, Y. L., Li, T., Zeng, M. S., & Sun, C. (2025). Applications of Artificial Intelligence in Biotech Drug Discovery and Product Development. MedComm, 6(8). https://doi.org/10.1002/mco2.70317
Vancouver
Liu YT, Zhang LL, Jiang ZY, Tian XS, Li PL, Wu PH, et al. Applications of Artificial Intelligence in Biotech Drug Discovery and Product Development. MedComm. 2025;6(8). doi:10.1002/mco2.70317
BibTeX
@article{Liu2025,
author = {Liu, Yuan-Tao and Zhang, Le-Le and Jiang, Zi-Ying and Tian, Xian-Shu and Li, Peng-Lin and Wu, Pei-Huang and Du, Wen-Ting and Yuan, Bo-Yu and Xie, Chu and Bu, Guo-Long and Zhong, Lan-Yi and Yang, Yan-Lin and Li, Ting and Zeng, Mu-Sheng and Sun, Cong},
title = {Applications of Artificial Intelligence in Biotech Drug Discovery and Product Development},
journal = {MedComm},
year = {2025},
volume = {6},
number = {8},
doi = {10.1002/mco2.70317}
}
EUVIMED